These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8701990)

  • 1. Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components.
    Wolf NG; Abdul-Karim FW; Schork NJ; Schwartz S
    Am J Pathol; 1996 Aug; 149(2):511-20. PubMed ID: 8701990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?
    Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A
    J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas.
    Zheng J; Wan M; Zweizig S; Velicescu M; Yu MC; Dubeau L
    Cancer Res; 1993 Sep; 53(18):4138-42. PubMed ID: 8364906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cytogenetics, interphase cytogenetics, and DNA flow cytometry in bone tumors.
    Tarkkanen M; Nordling S; Böhling T; Kivioja A; Karaharju E Szymanska J; Elomaa I; Knuutila S
    Cytometry; 1996 Sep; 26(3):185-91. PubMed ID: 8889389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings.
    Al-Mefty O; Kadri PA; Pravdenkova S; Sawyer JR; Stangeby C; Husain M
    J Neurosurg; 2004 Aug; 101(2):210-8. PubMed ID: 15309910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
    Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
    Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interphase cytogenetic analysis of mucinous ovarian neoplasms.
    Diebold J; Siegert S; Baretton GB; Suchy B; Meier W; Haas CJ; Löhrs U
    Lab Invest; 1997 May; 76(5):661-70. PubMed ID: 9166285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CyclinD1 copy number changes with histological type in ovarian tumors.
    Dimova I; Zaharieva B; Raicheva S; Milev I; Dimitrov R; Doganov N; Aleksandrov M; Todorov T; Toncheva D
    Acta Oncol; 2004; 43(7):675-9. PubMed ID: 15545188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
    Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
    Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: correlation with p53 protein overexpression and Ki-67.
    Kohlberger PD; Kieback DG; Mian C; Wiener H; Kainz C; Gitsch G; Breitenecker G
    J Soc Gynecol Investig; 1997; 4(5):262-4. PubMed ID: 9360232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early involvement of 6q in surface epithelial ovarian tumors.
    Tibiletti MG; Bernasconi B; Furlan D; Riva C; Trubia M; Buraggi G; Franchi M; Bolis P; Mariani A; Frigerio L; Capella C; Taramelli R
    Cancer Res; 1996 Oct; 56(19):4493-8. PubMed ID: 8813146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interphase cytogenetic analysis of single cell suspensions prepared from previously formalin-fixed and paraffin-embedded tissues.
    Kuchinka BD; Kalousek DK; Lomax BL; Harrison KJ; Barrett IJ
    Mod Pathol; 1995 Feb; 8(2):183-6. PubMed ID: 7777481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
    Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
    Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways.
    Körner M; Burckhardt E; Mazzucchelli L
    J Pathol; 2005 Sep; 207(1):20-6. PubMed ID: 16021676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interphase fluorescence in situ hybridization analysis detects a much higher rate of thyroid tumors with clonal cytogenetic deviations of the main cytogenetic subgroups than conventional cytogenetics.
    Drieschner N; Rippe V; Laabs A; Dittberner L; Nimzyk R; Junker K; Rommel B; Kiefer Y; Belge G; Bullerdiek J; Sendt W
    Cancer Genet; 2011 Jul; 204(7):366-74. PubMed ID: 21872823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrastructural study of benign, low-malignant potential (LMP), and malignant ovarian tumors.
    Ishioka S; Sagae S; Ito E; Kudo R
    Med Electron Microsc; 2004 Mar; 37(1):37-44. PubMed ID: 15057603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
    Evans MF; McDicken IW; Herrington CS
    J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of DNA flow cytometry in borderline malignant ovarian tumors.
    Lai CH; Hsueh S; Chang TC; Tseng CJ; Huang KG; Chou HH; Chen SM
    Cancer; 1996 Aug; 78(4):794-802. PubMed ID: 8756374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent cytogenetic aberrations in human ovarian carcinomas.
    Kiechle-Schwarz M; Bauknecht T; Schmidt J; Walz L; Pfleiderer A
    Cancer Detect Prev; 1995; 19(3):234-43. PubMed ID: 7750111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.